HLA typing analysis of RA and HS subjects who received an adalimumab treatment, revealed that specific HLA-DRB1 and HLA-DBQ1 alleles are associated with risk of or protection against AAA formation, respectively. This evidence concerns the gene HLA-DRB1 and triple-A syndrome.